{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:29:50Z","timestamp":1789752590452,"version":"4.0.1"},"reference-count":25,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Long-acting injectable cabotegravir\/rilpivirine (CAB\/RPV-LA) is currently approved as a maintenance therapy for people with HIV (PWH) who are virologically suppressed. However, growing real-world evidence highlights its potential role in more complex viremic populations traditionally considered ineligible. We present a case series of eight PWH treated at two tertiary centers in Italy, all of whom faced persistent viremia, adherence difficulties, malabsorption syndromes, or psychosocial barriers. Following the switch to CAB\/RPV-LA, all patients, despite heterogeneous clinical profiles and baseline virological status, achieved and maintained virologic suppression, demonstrated improved adherence, and experienced no serious adverse events.<\/jats:p>","DOI":"10.3390\/v17091254","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T07:07:18Z","timestamp":1758092838000},"page":"1254","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Experience with Long-Acting Injectable Cabotegravir\/Rilpivirine in HIV Patients with Unsuppressed Viral Load"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-5139","authenticated-orcid":false,"given":"Marcello","family":"Trizzino","sequence":"first","affiliation":[{"name":"Infectious and Tropical Diseases Unit and Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico \u201cP. Giaccone,\u201d 90133 Palermo, Italy"},{"name":"Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-4285","authenticated-orcid":false,"given":"Luca","family":"Pipit\u00f2","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit and Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico \u201cP. Giaccone,\u201d 90133 Palermo, Italy"},{"name":"Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy"},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties \u201cG D\u2019Alessandro,\u201d University of Palermo, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7559-7364","authenticated-orcid":false,"given":"Pierluigi Francesco","family":"Salvo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medical and Surgical Sciences, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zimmerhofer","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit and Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico \u201cP. Giaccone,\u201d 90133 Palermo, Italy"},{"name":"Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy"},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties \u201cG D\u2019Alessandro,\u201d University of Palermo, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cicero","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit and Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico \u201cP. Giaccone,\u201d 90133 Palermo, Italy"},{"name":"Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy"},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties \u201cG D\u2019Alessandro,\u201d University of Palermo, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-9976","authenticated-orcid":false,"given":"Gianmaria","family":"Baldin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medical and Surgical Sciences, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy"},{"name":"Department of Safety and Bioethics, Infectious Diseases Section, Catholic University of the Sacred Heart, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Conti","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit and Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico \u201cP. Giaccone,\u201d 90133 Palermo, Italy"},{"name":"Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy"},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties \u201cG D\u2019Alessandro,\u201d University of Palermo, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gio\u00e8","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit and Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico \u201cP. Giaccone,\u201d 90133 Palermo, Italy"},{"name":"Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medical and Surgical Sciences, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy"},{"name":"Department of Safety and Bioethics, Infectious Diseases Section, Catholic University of the Sacred Heart, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-1796","authenticated-orcid":false,"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit and Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico \u201cP. Giaccone,\u201d 90133 Palermo, Italy"},{"name":"Palermo Fast-Track City, Casa dei Diritti, 90100 Palermo, Italy"},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties \u201cG D\u2019Alessandro,\u201d University of Palermo, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jiph.2023.08.023","article-title":"Causes of hospitalization and predictors of in-hospital mortality among people living with HIV in Sicily-Italy between 2010 and 2021","volume":"16","author":"Zinna","year":"2023","journal-title":"J. Infect. Public Heath"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/09564624231169329","article-title":"Barriers to adherence to antiretroviral therapy: Identifying priority areas for people with HIV and healthcare professionals","volume":"34","author":"Mate","year":"2023","journal-title":"Int. J. STD AIDS"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: A randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/jac\/dkae480","article-title":"Safety and efficacy of long-acting cabotegravir\/rilpivirine versus standard oral antiretroviral therapy: A systematic review and meta-analysis","volume":"80","author":"Manalu","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","unstructured":"FDA (2025, August 01). Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection, Available online: https:\/\/www.fda.gov\/drugs\/human-immunodeficiency-virus-hiv\/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection."},{"key":"ref_6","unstructured":"(2025, August 01). First Long-Acting Injectable Antiretroviral Therapy for HIV Recommended for Approval. Available online: https:\/\/www.ema.europa.eu\/en\/news\/first-long-acting-injectable-antiretroviral-therapy-hiv-recommended-approval."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting Injectable Cabotegravir\/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy","volume":"78","author":"Brock","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/hiv.70025","article-title":"Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta-analysis","volume":"26","author":"Barda","year":"2025","journal-title":"HIV Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"ofad390","DOI":"10.1093\/ofid\/ofad390","article-title":"Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers","volume":"10","author":"Chen","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0000000000003421","article-title":"Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir\u2013Rilpivirine in People With HIV Who Are Virally Unsuppressed","volume":"96","author":"Hickey","year":"2024","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgar.2023.07.006","article-title":"Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort","volume":"34","author":"Cervo","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Iannone, V., Rossotti, R., Bana, N.B., Cavazza, G., D\u2019aMico, F., Lombardi, F., Salvo, P.F., Baldin, G., Di Giambenedetto, S., and Bernacchia, D. (2025). Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-10499-0"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hastie, E., Hill, L., Bamford, L., Karim, A., and Martin, T.C.S. (2025). Long-Acting Injectable Human Immunodeficiency Virus (HIV) Therapy Outcomes Among Persons with HIV Who Have Adherence Challenges to Oral Antiretroviral Therapy. Clin. Infect. Dis., ciaf120.","DOI":"10.1093\/cid\/ciaf120"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jpids\/piae033","article-title":"Off-label Use of Long-Acting Injectable Antiretroviral Therapy: A Single Center Retrospective Review of Youth Living with HIV with Detectable HIV RNA Starting Injectable Therapy","volume":"13","author":"Rousseau","year":"2024","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofae023","DOI":"10.1093\/ofid\/ofae023","article-title":"Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures","volume":"11","author":"Thoueille","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jac\/dkae080","article-title":"Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals","volume":"79","author":"Cossu","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofae480","DOI":"10.1093\/ofid\/ofae480","article-title":"Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection\u2014A Case Series of Five Patients with One Virologic Failure After Development of Two-Class Resistance","volume":"11","author":"Gerstenberg","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ofad604","DOI":"10.1093\/ofid\/ofad604","article-title":"Long-Acting Cabotegravir\/Rilpivirine Concentrations in Combination with Intravenous Rifampin: A Case Report","volume":"10","author":"Sunagawa","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12981-022-00477-w","article-title":"Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: An illustrative case series","volume":"19","author":"Kilcrease","year":"2022","journal-title":"AIDS Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ofae125","DOI":"10.1093\/ofid\/ofae125","article-title":"Case Series of People with HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial","volume":"11","author":"Gandhi","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lara-Aguilar, V., Llamas-Ad\u00e1n, M., Brochado-Kith, \u00d3., Crespo-Bermejo, C., Grande-Garc\u00eda, S., Arca-Lafuente, S., Santos, I.d.L., Prado, C., Al\u00eda, M., and Sainz-Pin\u00f3s, C. (2024). Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era. J. Biomed. Sci., 31.","DOI":"10.1186\/s12929-024-01064-z"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1097\/QAD.0000000000003984","article-title":"CD4+\/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine","volume":"38","author":"Muccini","year":"2024","journal-title":"AIDS"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): A randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/9\/1254\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:49Z","timestamp":1760035609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/9\/1254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["v17091254"],"URL":"https:\/\/doi.org\/10.3390\/v17091254","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}